Insider Selling: Charles River Laboratories International (NYSE:CRL) Director Sells $10,068,300.00 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director James Foster sold 33,561 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the completion of the transaction, the director directly owned 31,596 shares of the company’s stock, valued at approximately $9,478,800. This represents a 51.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Down 1.6%

Shares of NYSE CRL opened at $291.80 on Friday. The firm has a market cap of $13.93 billion, a P/E ratio of -60.16, a price-to-earnings-growth ratio of 3.03 and a beta of 1.38. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. Charles River Laboratories International, Inc. has a 1 year low of $144.26 and a 1 year high of $303.30. The firm’s 50 day moving average price is $246.06 and its 200 day moving average price is $197.30.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. During the same period in the previous year, the firm posted $3.12 EPS. Charles River Laboratories International’s revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.33 earnings per share for the current year.

Institutional Trading of Charles River Laboratories International

A number of hedge funds have recently made changes to their positions in CRL. California State Teachers Retirement System grew its holdings in Charles River Laboratories International by 22,535.2% during the 2nd quarter. California State Teachers Retirement System now owns 12,895,733 shares of the medical research company’s stock valued at $2,924,623,000 after purchasing an additional 12,838,761 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Charles River Laboratories International by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after buying an additional 47,432 shares in the last quarter. Invesco Ltd. boosted its position in Charles River Laboratories International by 115.8% in the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after buying an additional 1,446,972 shares during the last quarter. State Street Corp grew its stake in shares of Charles River Laboratories International by 2.2% during the fourth quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock valued at $373,364,000 after acquiring an additional 40,535 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Charles River Laboratories International by 14.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after acquiring an additional 210,260 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on CRL. Morgan Stanley boosted their price objective on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. JPMorgan Chase & Co. raised Charles River Laboratories International from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $180.00 to $310.00 in a research report on Thursday, August 6th. Piper Sandler set a $300.00 target price on Charles River Laboratories International in a report on Monday, August 10th. Mizuho set a $264.00 price target on Charles River Laboratories International in a research note on Monday, August 10th. Finally, Royal Bank Of Canada raised their price objective on Charles River Laboratories International from $215.00 to $282.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $255.65.

Charles River Laboratories International News Summary

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Long-term earnings outlook improved. Zacks Research raised its EPS forecasts for fiscal 2026 to $11.15 from $10.91, fiscal 2027 to $12.49 from $12.11, and fiscal 2028 to $13.82 from $13.01. Estimates also increased for several future quarters, signaling greater confidence in CRL’s longer-term growth prospects.
• Positive Sentiment: Enterovirus vaccine collaboration could generate future demand. Medigen has partnered with Charles River in an effort to bring an enterovirus vaccine to global markets. The initiative could create additional opportunities for CRL’s contract research, testing, and development services. Medigen links up with Charles River in push to take enterovirus vaccine global
• Neutral Sentiment: Recent operating results provide a mixed backdrop. CRL’s latest quarterly EPS of $3.02 exceeded the $2.77 consensus estimate, and revenue reached approximately $1 billion. However, revenue declined 2.7% year over year, while the company’s full-year 2026 EPS guidance remains $11.15-$11.45, close to the analyst consensus.
• Negative Sentiment: Director sold a sizable stake. James C. Foster sold 33,561 shares for about $10.1 million at an average price of $300, reducing his direct ownership by 51.5%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which makes it a less definitive bearish signal, but the size of the sale may pressure investor sentiment. SEC insider transaction filing
• Negative Sentiment: Some near-term estimates were lowered. Zacks trimmed its EPS forecasts for the third and fourth quarters of 2026, the first quarter of 2027, and the fourth quarter of 2027. These modest cuts suggest near-term uncertainty despite the stronger full-year and longer-term projections.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.